Pfizer, Starboard
Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...
As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...
Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...
Pfizer taps Triana to discover molecular glues for cancer and beyond in deal potentially worth $1.5B
Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on ...
Pfizer is already active in the protein degrader area, having partnered with Arvinas in a $2 billion-plus deal signed in 2021 focusing on vepdegestrant (ARV-471), an orally active selective oestrogen ...
Now, despite playing no formal role in the battle between Pfizer and Starboard, Guggenheim has found itself in the crossfire of one of the messiest activist campaigns in recent Wall Street memory.
Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said they will not be involved with activist investor Starboard Value, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback